Laryngeal DiseaseNIRS_ORLNCT05400642
Randomized Controlled Trial:High-flow Oxygen Therapy and Tracheal Intubation for Laryngeal Microsurgery
A study testing THRIVE and mechanical ventilation in people with Laryngeal Disease, run by Fondazione Policlinico Universitario Agostino Gemelli IRCCS at 1 site in Italy.
Trial summary
Over time, the accumulation of carbon dioxide reduces the pressure gradient for the alveolar transfer of oxygen, limiting the successful duration of apneic oxygenation. NIRS (Near-Infrared Spectroscopy) technology is able to provide an estimate of the regional balance between demand and supply of brain oxygen. Read more about this study
- Who is it for?
- Ages 18 to 69 years
- Conditions the study is for
- Laryngeal Disease
- What is being tested?
- THRIVE and mechanical ventilation
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteItaly
- Study dates
- 1 Sep 2022to 30 Jun 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 69 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- ASA I and II. Scheduled for Microlaryngeal surgery
Who cannot join
- age < 18 years;
- pregnancy status;
- NYHA class > III;
- BMI > 30;
- pre-existing cardiac arrhythmias;
- high risk of inhalation;
- neuromuscular diseases or metabolite accumulation;
- refusal of informed consent or impossibility to express it.
Trial locations and contacts
1 site in 1 country.
Italy1 site, 1 recruiting
- Recruiting
Fabio Sbaraglia
Roma, 00135
fabio sbaraglia, 3497730144, fabiosbaraglia@hotmail.com
About this study
Official title: SctO2 Evaluated by NIRS Between Apneic Oxygenation With High-flow Oxygen Therapy and Tracheal Intubation During Laryngeal Microsurgery: a Prospective Non-inferiority RCT
Over time, the accumulation of carbon dioxide reduces the pressure gradient for the alveolar transfer of oxygen, limiting the successful duration of apneic oxygenation. NIRS (Near-Infrared Spectroscopy) technology is able to provide an estimate of the regional balance between demand and supply of brain oxygen.
The primary hypothesis of this study is that although high-flow oxygen therapy may be associated with transiently higher PaCO2 values than those found in patients undergoing tracheal intubation and traditional mechanical ventilation, due to the brevity of this phenomenon the variations in the average values of frontal cerebral tissue oxygen saturation are expected to be of similar magnitude between the two groups.
Read more
Secondary objectives will be the comparison of the success rate of high-flow oxygen therapy compared to traditional airway management by mechanical ventilation.
The success rate will be defined as blood pressure of carbon dioxide (PaCO2) <= 65 mmHg and/or peripheral oxygen saturation (SpO2) >= 94% throughout the procedure, in the absence of adverse events (haemodynamic alteration, dyspnea, discomfort).
The data will be analyzed according to an intention-to-treat principle. Continuous variables with repeated measurements will be compared with a mixed-effect linear regression model. Normality of distribution will be verified with the Shapiro-Wilk test. Continuous variables will be compared with Student t- or Mann-Whitney test; categorical variables with the Chi-square test.
Read the detailed description
Apneic oxygenation is a physiological phenomenon in which, provided that patency exists between the lungs and the external environment, the pulmonary flow of oxygen is maintained by a negative pressure gradient generated by the difference between the rate of alveolar extraction of oxygen and the excretion of carbon dioxide.
Over time, the accumulation of carbon dioxide reduces the pressure gradient for the alveolar transfer of oxygen, limiting, because of a condition of acidosis, the successful duration of apneic oxygenation.
The effects of hypercapnia on the mechanisms of cerebral blood flow autoregulation are well known and NIRS (Near-Infrared Spectroscopy) technology, through the non-invasive analysis of the relative absorbance of oxy- and deoxyhemoglobin in the frontal cerebral tissue microcirculation, is able to provide an estimate of the regional balance between demand and supply of brain oxygen.
High-Flow Nasal Cannula Oxygenation (HFNCO) is an open-loop oxygenation system that uses flows of up to 70 l/min of 100% oxygen through the Optiflow THRIVETM apparatus (Fisher and Paykel Healthcare Ltd, Auckland, New Zealand), increasingly used as an alternative to tracheal intubation in patients undergoing short-term general anesthesia.
Heating and humidification of the flows facilitate their tolerability by the patient; HFNCO produces a linear, flow-dependent effect of continuous positive airway pressure about 1 cmH20 for every 10 l/min increase in oxygen flows, reduces dead space and allows elimination of carbon dioxide, with the potential to increase alveolar volume and improve gas exchanges.
The efficacy of HFNCO in apneic patients undergoing laryngeal surgery is debated: on the one hand it allows minimal manipulation of the airways by the anesthesiologist, it expands the surgical field and it proved to be not inferior to tracheal intubation in maintaining oxygen saturation, however it has been associated with a higher incidence of hypercapnia and the need for rescue maneuvers of airway management.
Laryngeal microsurgery includes procedures usually lasting < 30 minutes, performed under general anesthesia and tracheal intubation.
The primary hypothesis of this study is that although high-flow oxygen therapy may be associated with transiently higher PaCO2 values than those found in patients undergoing tracheal intubation and traditional mechanical ventilation, due to the brevity of this phenomenon the variations in the average values of frontal cerebral tissue oxygen saturation are expected to be of similar magnitude between the two groups.
Secondary objectives will be the comparison of the success rate of high-flow oxygen therapy compared to traditional airway management by mechanical ventilation.
The success rate will be defined as blood pressure of carbon dioxide (PaCO2) <= 65 mmHg and/or peripheral oxygen saturation (SpO2) >= 94% throughout the procedure, in the absence of adverse events.
The maximum arterial concentration of carbon dioxide achieved during the procedure, the percentage of complications in terms of inability to manage the airways with the need for tracheal intubation in the group treated with high-flow oxygen therapy, episodes of hypotension, cardiac arrhythmias and post-operative nausea and vomiting will also be compared; finally, the degree of dyspnea (with the Borg dyspnea score) and patient comfort (Visual Analogue Scale) at the end of the procedure will be evaluated.
The data will be analyzed according to an intention-to-treat principle. Clinical and demographic characteristics of the sample will be described through descriptive statistical techniques. Continuous quantitative variables with normal distribution will be reported as mean and standard deviation; as median and interquartile range the non-normal variables.
The confidence intervals for median differences will be calculated by the Hodges-Lehman method.
Categorical variables and missing data will be presented as absolute value and percentage, n (%). Continuous variables will be compared with the Student t-test in case of normal distribution or, if not, with the Mann-Whitney test for independent samples. The normality of the distribution of the variables will be verified graphically by histograms and with the Shapiro-Wilk test.
Differences between categorical variables will be analyzed using the Chi-square test or the Fisher's exact test in case of expected frequencies < 5.
For each participant, for SctO2, a combined average will be calculated (SctO2 left + SctO2 right/2).
Continuous variables with repeated measurements will be compared with a mixed-effect linear regression model, with correction according to Bonferroni's method. The type of airway management used and the timing at which the measurements will be performed will be considered as fixed effects; a random effect related to the patient will also be added.
- Conditions
- Laryngeal Disease
- Being tested
- THRIVE, mechanical ventilation
- Keywords
- general anesthesia, hfnco, NIRS
- Medical subject headings
- Laryngeal Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
THRIVEDevice
Apneic ventilation
mechanical ventilationDevice
mechanical ventilation in Positive Pressure
| Study group | Role | What they receive |
|---|---|---|
| High Flow Oxygen Therapy | Experimental | Surgery conducted under High Flow Oxygen Therapy Receives: Device: THRIVE |
| Mechanical ventilation | Active comparator | Surgery conducted under orotracheal intubation and mechanical ventilation Receives: Device: mechanical ventilation |
What is being measured
The primary outcome is the main question the study is designed to answer.
NIRS
Average values of frontal cerebral tissue oxygen saturation
Measured: each five minutes from anesthesia induction up to the end of surgery
Secondary outcomes (1)
The success rate of high-flow oxygen therapy compared to traditional airway management by mechanical ventilation.
The success rate will be defined as blood pressure of carbon dioxide (PaCO2) <= 65 mmHg and/or peripheral oxygen saturation (SpO2) >= 94% throughout the procedure, in the absence of adverse events.
Measured: each five minutes from anesthesia induction up to the end of surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Jun 2022
- Study start1 Sep 2022
- Primary completion30 Jun 2023 (estimated)
- Study completion30 Jun 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Laryngeal DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- fabio sbaraglia, phD, Principal investigator, Fondazione Policlinico Gemelli IRCCS
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05400642
- Sponsor's protocol ID
- 4953
- Acronym
- NIRS_ORL
- Status last verified
- Dec 2022
- First submitted
- 23 May 2022
- Last updated
- 8 Dec 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Dec 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- SctO2 Evaluated by NIRS Between Apneic Oxygenation With High-flow Oxygen Therapy and Tracheal Intubation During Laryngeal Microsurgery: a Prospective Non-inferiority RCT
- ClinicalTrials.gov ID
- NCT05400642
- Acronym / sponsor ID
- NIRS_ORL / 4953
- Conditions
- Laryngeal Disease
- Keywords
- general anesthesia, hfnco, NIRS
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCSUniversity, hospital or other
- Study start
- 1 Sep 2022 (actual)
- Primary completion
- 30 Jun 2023 (estimated)
- Study completion
- 30 Jun 2023 (estimated)
- First posted
- 1 Jun 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Over time, the accumulation of carbon dioxide reduces the pressure gradient for the alveolar transfer of oxygen, limiting the successful duration of apneic oxygenation. NIRS (Near-Infrared Spectroscopy) technology is able to provide an estimate of the regional balance between demand and supply of brain oxygen.
The primary hypothesis of this study is that although high-flow oxygen therapy may be associated with transiently higher PaCO2 values than those found in patients undergoing tracheal intubation and traditional mechanical ventilation, due to the brevity of this phenomenon the variations in the average values of frontal cerebral tissue oxygen saturation are expected to be of similar magnitude between the two groups.
Secondary objectives will be the comparison of the success rate of high-flow oxygen therapy compared to traditional airway management by mechanical ventilation.
The success rate will be defined as blood pressure of carbon dioxide (PaCO2) <= 65 mmHg and/or peripheral oxygen saturation (SpO2) >= 94% throughout the procedure, in the absence of adverse events (haemodynamic alteration, dyspnea, discomfort).
The data will be analyzed according to an intention-to-treat principle. Continuous variables with repeated measurements will be compared with a mixed-effect linear regression model. Normality of distribution will be verified with the Shapiro-Wilk test. Continuous variables will be compared with Student t- or Mann-Whitney test; categorical variables with the Chi-square test.
Detailed description
Apneic oxygenation is a physiological phenomenon in which, provided that patency exists between the lungs and the external environment, the pulmonary flow of oxygen is maintained by a negative pressure gradient generated by the difference between the rate of alveolar extraction of oxygen and the excretion of carbon dioxide.
Over time, the accumulation of carbon dioxide reduces the pressure gradient for the alveolar transfer of oxygen, limiting, because of a condition of acidosis, the successful duration of apneic oxygenation.
The effects of hypercapnia on the mechanisms of cerebral blood flow autoregulation are well known and NIRS (Near-Infrared Spectroscopy) technology, through the non-invasive analysis of the relative absorbance of oxy- and deoxyhemoglobin in the frontal cerebral tissue microcirculation, is able to provide an estimate of the regional balance between demand and supply of brain oxygen.
High-Flow Nasal Cannula Oxygenation (HFNCO) is an open-loop oxygenation system that uses flows of up to 70 l/min of 100% oxygen through the Optiflow THRIVETM apparatus (Fisher and Paykel Healthcare Ltd, Auckland, New Zealand), increasingly used as an alternative to tracheal intubation in patients undergoing short-term general anesthesia.
Heating and humidification of the flows facilitate their tolerability by the patient; HFNCO produces a linear, flow-dependent effect of continuous positive airway pressure about 1 cmH20 for every 10 l/min increase in oxygen flows, reduces dead space and allows elimination of carbon dioxide, with the potential to increase alveolar volume and improve gas exchanges.
The efficacy of HFNCO in apneic patients undergoing laryngeal surgery is debated: on the one hand it allows minimal manipulation of the airways by the anesthesiologist, it expands the surgical field and it proved to be not inferior to tracheal intubation in maintaining oxygen saturation, however it has been associated with a higher incidence of hypercapnia and the need for rescue maneuvers of airway management.
Laryngeal microsurgery includes procedures usually lasting < 30 minutes, performed under general anesthesia and tracheal intubation.
The primary hypothesis of this study is that although high-flow oxygen therapy may be associated with transiently higher PaCO2 values than those found in patients undergoing tracheal intubation and traditional mechanical ventilation, due to the brevity of this phenomenon the variations in the average values of frontal cerebral tissue oxygen saturation are expected to be of similar magnitude between the two groups.
Secondary objectives will be the comparison of the success rate of high-flow oxygen therapy compared to traditional airway management by mechanical ventilation.
The success rate will be defined as blood pressure of carbon dioxide (PaCO2) <= 65 mmHg and/or peripheral oxygen saturation (SpO2) >= 94% throughout the procedure, in the absence of adverse events.
The maximum arterial concentration of carbon dioxide achieved during the procedure, the percentage of complications in terms of inability to manage the airways with the need for tracheal intubation in the group treated with high-flow oxygen therapy, episodes of hypotension, cardiac arrhythmias and post-operative nausea and vomiting will also be compared; finally, the degree of dyspnea (with the Borg dyspnea score) and patient comfort (Visual Analogue Scale) at the end of the procedure will be evaluated.
The data will be analyzed according to an intention-to-treat principle. Clinical and demographic characteristics of the sample will be described through descriptive statistical techniques. Continuous quantitative variables with normal distribution will be reported as mean and standard deviation; as median and interquartile range the non-normal variables.
The confidence intervals for median differences will be calculated by the Hodges-Lehman method.
Categorical variables and missing data will be presented as absolute value and percentage, n (%). Continuous variables will be compared with the Student t-test in case of normal distribution or, if not, with the Mann-Whitney test for independent samples. The normality of the distribution of the variables will be verified graphically by histograms and with the Shapiro-Wilk test.
Differences between categorical variables will be analyzed using the Chi-square test or the Fisher's exact test in case of expected frequencies < 5.
For each participant, for SctO2, a combined average will be calculated (SctO2 left + SctO2 right/2).
Continuous variables with repeated measurements will be compared with a mixed-effect linear regression model, with correction according to Bonferroni's method. The type of airway management used and the timing at which the measurements will be performed will be considered as fixed effects; a random effect related to the patient will also be added.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| High Flow Oxygen Therapy | Experimental | Device: THRIVESurgery conducted under High Flow Oxygen Therapy |
| Mechanical ventilation | Active comparator | Device: mechanical ventilationSurgery conducted under orotracheal intubation and mechanical ventilation |
Who may qualify
- Ages
- 18 to 69 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- ASA I and II. Scheduled for Microlaryngeal surgery
Key exclusion criteria (8 listed)
- age < 18 years;
- pregnancy status;
- NYHA class > III;
- BMI > 30;
- pre-existing cardiac arrhythmias;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| THRIVEApneic ventilation | Device | High Flow Oxygen Therapy |
| mechanical ventilationmechanical ventilation in Positive Pressure | Device | Mechanical ventilation |
Primary outcome
NIRS
Time frame: each five minutes from anesthesia induction up to the end of surgery
Average values of frontal cerebral tissue oxygen saturation
1 secondary outcome
The success rate of high-flow oxygen therapy compared to traditional airway management by mechanical ventilation.
Time frame: each five minutes from anesthesia induction up to the end of surgery
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Dec 2022.
- Individual participant dataSharing planned: No
Related trials for Laryngeal Disease
Not yet recruitingPhase 2
Combination Bevacizumab and PRGN-2012 in Adults With Recurrent Respiratory Papillomatosis (RRP)
Respiratory Recurrent Papillomatosis (RRP), Human Papillomavirus (HPV)
Not yet recruiting
Endotracheal Tube Versus Transcartilage Needle Electrodes for Nerve Monitoring in Thyroid Surgery
Thyroid Diseases, Recurrent Laryngeal Nerve Injury
RecruitingObservational study
Biospecimen Procurement for Head and Neck Disorders
Hearing Disorder, Oral Mucosal Disease
RecruitingPhase 2/3
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
RecruitingObservational study
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Rare Disorders, Undiagnosed Disorders
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
fabio sbaraglia, phD principal investigator
Fondazione Policlinico Gemelli IRCCS
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing THRIVE and mechanical ventilation in people with Laryngeal Disease, run by Fondazione Policlinico Universitario Agostino Gemelli IRCCS at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 8 Dec 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact fabio sbaraglia, Ph.D (3497730144, fabio.sbaraglia@policlinicogemelli.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
NIRS (time frame: each five minutes from anesthesia induction up to the end of surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Dec 2022; AzTrials last refreshed its copy on 31 Oct 2026.